Patients with therapy-related myelodysplastic syndromes and acute myeloid leukemia share genetic features but can be separated by blast counts and cytogenetic risk profiles into prognostically relevant subgroups

Leukemia and Lymphoma

Volumn 54, Issue 3, 2013, Pages 639-642

  Bacher, Ulrike ^a   Haferlach, Claudia ^a   Alpermann, Tamara ^a   Schnittger, Susanne ^a   Kern, Wolfgang ^a   Haferlach, Torsten ^a  

^a MLL MUNICH LEUKEMIA LABORATORY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CD135 ANTIGEN; HEMOGLOBIN; MIXED LINEAGE LEUKEMIA PROTEIN; NUCLEOPHOSMIN; TRANSCRIPTION FACTOR RUNX1;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CELL STRUCTURE; CHROMOSOME BANDING PATTERN; CLINICAL FEATURE; COHORT ANALYSIS; CYTOGENETICS; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE MUTATION; GENOTYPE; HEMOGLOBIN BLOOD LEVEL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KARYOTYPE; LETTER; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MUTATION RATE; MYELODYSPLASTIC SYNDROME; OUTCOME ASSESSMENT; PRIORITY JOURNAL; THROMBOCYTE COUNT;

ACUTE DISEASE; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BLAST CRISIS; CHEMORADIOTHERAPY; CYTOGENETICS; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; LEUKEMIA, MYELOID; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PROGNOSIS; RISK FACTORS; SURVIVAL ANALYSIS; YOUNG ADULT;

EID: 84873381393     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2012.717275     Document Type: Letter

References (9)

1. Vardiman JW, Arber D, Brunning R, et al. Therapy-related myeloid neoplasms. In: Swerdlow S, Campo E, Harris NL, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon, IARC Press: 2008, pp 127-129.
2. Singh ZN, Huo D, Anastasi J, et al. Therapy-related myelodysplastic syndrome: morphologic subclassification may not be clinically relevant. Am J Clin Pathol 2007;127: 197-205.
3. Buchner T, Berdel WE, Haferlach C, et al. Age-related risk profile and chemotherapy dose response in acute myeloid leukemia: a study by the German Acute Myeloid Leukemia Cooperative Group. J Clin Oncol 2009;27: 61-69.
4. Grimwade D, Hills RK, Moorman AV, et al. Refnement of cytogenetic classification in acute myeloid leukemia: determination of prognostic signif cance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood 2010;116: 354-365.
5. Schnittger S, Schoch C, Kern W, et al. Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype. Blood 2005;106: 3733-3739.
6. Tiede C, Koch S, Creutzig E, et al. Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML). Blood 2006;107: 4011-4020.
7. Bains A, Luthra R, Medeiros LJ, et al. FLT3 and NPM1 mutations in myelodysplastic syndromes: frequency and potential value for predicting progression to acute myeloid leukemia. Am J Clin Pathol 2011;135: 62-69.
8. Schnittger S, Schoch C, Dugas M, et al. Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. Blood 2002;100: 59-66.
9. Kayser S, Dohner K, Krauter J, et al. The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML. Blood 2011;117: 2137-2145.